Methicillin-resistant Staphylococcus aureus, Hawaii, 2000–2002 by Li, Fenfang et al.
The emergence of methicillin-resistant Staphylococcus
aureus (MRSA) has generated considerable concern
among medical and public health professionals. We used a
statewide, population-based antimicrobial resistance sur-
veillance system to examine epidemiologic trends for
MRSA from outpatients and inpatients in Hawaii. Pediatric
and adult patient populations were compared to assess
characteristics of MRSA isolates specific for each group.
From 2000 to 2002, 8,206 (26%) of 31,482 total S. aureus
isolates were MRSA. During this period, the proportion of
MRSA isolates increased in both outpatient and inpatient
clinical settings (p<0.01). When stratified by age, annual
trends showed a significant increase in the proportion of
MRSA in adult patients (from 24% to 30%, p<0.01) but not
in pediatric patients (from 25% to 27%, p>0.05). Although
MRSAisolates from adults demonstrated high resistance to
most non–β-lactams, most MRSA isolates from pediatric
outpatients remained susceptible to most non–β-lactams.
F
irst detected in the 1960s, methicillin-resistant
Staphylococcus aureus (MRSA) has become the lead-
ing cause of nosocomial infections during the last 2
decades (1). MRSA isolates are increasingly resistant to
multiple non–β-lactam antimicrobial drugs. Recent reports
of vancomycin-resistant S. aureus foreshadow an era of
chemotherapy in which effective bactericidal drugs to treat
infection with this organism may not be readily available
(2,3). 
Established risk factors for MRSA infection include a
history of recent hospitalization or surgery, dialysis, resid-
ing in long-term care facilities, presence of an indwelling
catheter, and use of injectable drugs (4–6). More recently,
however, outbreaks of MRSA infections have been report-
ed in healthy persons without these previously recognized
risk factors in a variety of community settings (7–12). 
Preliminary work suggests that community isolates of
MRSA differ from their hospital counterparts in their
demographic, clinical, and molecular characteristics
(13–18). However, the epidemiology of MRSA in outpa-
tient settings has not been fully described. In particular,
knowledge is limited regarding the epidemiology of
MRSAin persons visiting hospital outpatient settings, pub-
lic or community health centers, and private physicians’
offices, i.e., settings where most MRSA infections are
treated and the greatest percentage of total antimicrobial
use occurs (19). The objective of this study was to better
characterize the epidemiology of MRSA from both inpa-
tient and outpatient settings in Hawaii by using a popula-
tion-based surveillance system.
Materials and Methods 
Data Collection 
Antimicrobial susceptibility test data, collected retro-
spectively through the State of Hawaii Antimicrobial
Resistance Project (SHARP) from 2000 to 2002, were
used for this analysis. The SHARP system captures elec-
tronic laboratory data from 2 large private clinical labora-
tories, which serve most of Hawaii’s total population (N =
1,211,537) (20). These 2 commercial laboratories provide
susceptibility testing services for >85% of all nonhospital
outpatient settings in Hawaii (21). They also perform sus-
ceptibility testing for 18 of 24 acute care hospitals in the
state, including the outpatient services associated with
these hospital facilities (22). The remaining 6 acute care
hospitals perform susceptibility testing in their own labo-
ratories. Data from 2 of these hospitals are incorporated
into the SHARP database, which provides a final dataset
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Isolate-level data, including the specimen collection
date, source (e.g., blood, urine, and cerebrospinal fluid),
susceptibility testing methods (e.g., Kirby-Bauer), and sus-
ceptibility test results, are provided by the laboratories par-
ticipating in SHARP. Limited demographic patient
information is also included in the record, e.g., date of
birth and sex. However, detailed clinical histories and
patient names are not available. In lieu of names, patients
were assigned personal identifiers created by concatenat-
ing values from the birth date, sex, reporting laboratory,
and hospital/clinic location of specimen collection. 
All cultures that yielded S. aureus isolates from 2000
through 2002 were identified, and any isolates from
patients in nonacute care beds (i.e., long-term care homes)
and correctional facilities were excluded. Duplicate iso-
lates were then removed according to Clinical and
Laboratory Standards Institute (formerly NCCLS) guide-
lines (23). Only the first isolate per patient, irrespective of
body site, antimicrobial susceptibility profile, or other phe-
notypic characteristics (e.g., biotype), in a defined period
(for our purposes, 90 days) was included. Therefore, after
the initial isolate, successive isolates for the same patient
during the next 90 days were excluded. 
The breakpoint for MRSA was an MIC >4 µg/mL or a
zone diameter ≤10 mm. The breakpoint for oxacillin
(methicillin)–intermediate isolates was an MIC 2–4 µg/mL
or a zone diameter from 11 to 12 mm. The breakpoint for
oxacillin (methicillin)–susceptible isolates was an MIC <2
µg/mLor a zone diameter >13 mm. Susceptibility interpre-
tations for other antimicrobial drugs were based also on
breakpoints established by NCCLS (24). 
Patient Classification 
Patients  ≤18 years of age were defined as pediatric
patients and those >19 years of age as adult patients.
Classification of inpatient or outpatient status was based
on patients’ location at the time of specimen collection.
Inpatient isolates were defined as those collected from
patients in both regular hospital wards and intensive care
units. Outpatient isolates were defined as those collected
from patients in 1) an outpatient department, emergency
department, ambulatory clinic, or same-day-surgery clinic
associated with a hospital, or 2) a private physician’s
office, community public health center, or university
health center. 
Data Analysis
The proportion of MRSAwas calculated as the number
of MRSAisolates divided by the total number of S. aureus
isolates during a defined period (e.g., per year) for a given
setting (e.g., inpatient) and population (e.g., pediatric). The
proportion of MRSAisolates resistant to a specific antimi-
crobial agent was calculated as the proportion of resistant
isolates divided by the total MRSA isolates tested against
the particular antimicrobial agent of interest during a
defined period. Categorical data analysis was performed
using EpiInfo version 6.04c statistical software (Centers
for Disease Control and Prevention, Atlanta, GA, USA).
Chi-square and Fisher exact tests were used to compare
proportions, and significance was defined as p<0.05. The
Kruskal-Wallis test was used to compare median age of
patients, and Pearson correlation coefficient was used to
determine the correlation of age and MRSAproportions in
different clinical settings.
Results 
Atotal of 41,250 S. aureus isolates were identified from
combined inpatient and outpatient settings from 2000 to
2002. After removal of duplicate data, 31,482 isolates
remained in the analysis; 23,550 were from outpatients,
and 7,932 were from hospital inpatients. A total of 8,206
(26%) of all isolates included in the analyses were MRSA.
The overall proportion of MRSAfrom 2000 to 2002 in out-
patients was 22% (5,135/23,550) versus 39%
(3,071/7,932) for inpatients (p<0.01). Although the pro-
portion of MRSA remained significantly higher in inpa-
tients compared with outpatients each year of the study, an
overall significant increase in the proportion of MRSA
infections was observed in both clinical settings during the
3-year study period (p<0.01, Table 1). The proportion of
MRSA isolates during the 3-year period was significantly
higher in pediatric outpatients (24%, 1,092/4,571) than
that in adult outpatients (21%, 4,043/18,979; p<0.01).
However, adult inpatients had a significantly higher pro-
portion of MRSA isolates (40%, 2,868/7,217) when com-
pared with pediatric inpatients (28%, 203/715; p<0.01).
A significant increase in the proportion of MRSA iso-
lates was observed in all adult patients (from 24% to 30%,
p<0.01) during the 3-year study period, and an increasing,
although not statistically significant, trend was observed in
pediatric patients (Figure 1). When the total MRSA iso-
lates for all study years were examined by 10-year age
groups, the proportion of MRSA isolates increased with
age in inpatients, but not in outpatients (Figure 2).
Correspondingly, inpatients with MRSA infections were
significantly older (median age 67 years) than outpatients
with MRSA infections (median age 44 years; p<0.01).
Of the 31,482 S. aureus isolates in the analysis, 31,240
(99%) had identifiable specimen sources. Table 2 summa-
rizes the frequency of MRSA anatomic specimen sources
for pediatric and adult patients in outpatient and inpatient
settings. Wounds were the most common specimen sources
for MRSA isolates in both pediatric and adult populations
in all clinical settings.
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to non–β-lactam antimicrobial agents was significantly
higher in inpatient isolates than in outpatient isolates for
nearly all of the antimicrobial agents tested (p<0.01, Table
3). For all years combined, a significantly higher level of
resistance to non–β-lactam antimicrobials was observed in
all adult MRSA isolates compared with all pediatric
MRSA isolates (p<0.01). Most MRSA isolates from pedi-
atric outpatients remained susceptible to most non–β-lac-
tams, with the exception of erythromycin, to which 24% of
the isolates were resistant.
Discussion
Our analyses identified an increase in the proportion of
MRSAfor both outpatient and inpatient settings in Hawaii
from 2000 through 2002. In the final year of the study, the
proportion of MRSA isolates in outpatients and inpatients
was notable, i.e., 25% and 42%, respectively.
Whereas high rates of MRSA in inpatient settings have
been described previously (1,14), our data highlight an
issue of more recent concern, i.e., increasing MRSAinfec-
tions occurring in the outpatient setting. In the absence of
detailed clinical histories, isolates obtained in the outpa-
tient setting cannot be equated to community-associated
MRSA. However, isolates from a large population of pedi-
atric outpatients may be a reasonable surrogate for com-
munity-associated  S. aureus infections because they
should reflect infections occurring in a predominantly
healthy, nonhospitalized population. Furthermore, previ-
ous studies have established that skin and soft tissue infec-
tions are the most common sources of community-
associated MRSA(16,25,26). In our setting, ≈25% of all S.
aureus infections from pediatric outpatients were MRSA,
with 95% of these isolated from wounds. These data sug-
gest that MRSA is an important cause of wound infections
in children in Hawaii, a finding consistent with a growing
number of reports of MRSA in pediatric outpatients else-
where (27,28).
Although the proportion of MRSA isolates was signifi-
cantly lower for adult outpatients compared with pediatric
outpatients (21% versus 24%, p<0.01), the total number of
MRSA infections in adult outpatients outnumbered those
in pediatric outpatients nearly 4:1. In addition, we
observed a positive correlation between the proportion of
MRSA isolates and advancing age for inpatients, but not
for outpatients (R = 0.92, p<0.01). This finding is not
unexpected if one considers that older adults are more like-
ly to have chronic illnesses that require more frequent hos-
pitalizations and, thus, potentially encounter increased
exposure to resistant microorganisms (1,4,5,14). 
MRSA isolates obtained from outpatient settings tend-
ed to be less resistant to nonoxacillin antimicrobial drugs
than their inpatient counterparts, as observed elsewhere
(12,14,16,25–28). Proportionally more pediatric isolates
remained susceptible to multiple non–β-lactams compared
with adult isolates, most notably when compared with
adult inpatient isolates. The dissimilar antimicrobial resist-
ance profiles observed between clinical settings may
reflect differences in cohorts of circulating MRSAisolates,
especially between outpatients and inpatients, as has been
demonstrated in other investigations (16,27,28).
Of clinical importance is that pediatric outpatient
MRSA isolates remained largely susceptible to most
non–β-lactams. However, ≈25% of pediatric outpatient
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Figure 1. Proportion of methicillin-resistant Staphylococcus aureus
(MRSA) in pediatric and adult patients, Hawaii, 2000-2002. Error
bars show 95% confidence intervals.MRSA isolates in Hawaii were resistant to erythromycin,
which is consistent with findings in other studies of MRSA
macrolide resistance in pediatric outpatients (25,27,28). In
contrast, only 7% of the pediatric outpatient isolates were
resistant to clindamycin. This antimicrobial drug has been
used to successfully treat MRSA infections in children in
community settings. However, clinicians should be aware
of inducible resistance to clindamycin due to methylation
of ribosomal RNA encoded by the genes ermA or ermC in
initially clindamycin-susceptible but erythromycin-resist-
ant  S. aureus isolates (25,29). Therefore, clindamycin
monotherapy should be avoided in critically ill children
with MRSA infections until inducible clindamycin resist-
ance has been excluded by double-disk testing (25,29,30). 
Amajor limitation of this study is the potential misclas-
sification of the clinical setting (i.e., outpatient versus
inpatient). Because of the lack of named personal identi-
fiers, patients could not be traced from isolates to be inter-
viewed, and medical records could not be reviewed.
Therefore, we could not directly correlate our findings for
outpatients and inpatients with the more conventional def-
initions of community-associated and nosocomial-associ-
ated MRSA, respectively. We assigned an isolate to a
clinical setting based on the location where the patient’s
specimen was collected, so misclassification was possible.
For example, a patient whose specimen was obtained in an
outpatient setting (e.g., an emergency department) may
have actually acquired S. aureus during a recent hospital-
ization. If misclassification of this type occurred, the dif-
ference in MRSA rates between outpatient and inpatient
isolates would be underestimated. However, this misclas-
sification type might be expected to remain consistent over
a 3-year period, so the observed temporal trends would
likely remain valid. Moreover, the significant differences
in resistance to nonoxacillin antimicrobial drugs observed
between outpatients and inpatients suggest that the MRSA
isolates from outpatients were not, on average, nosocomi-
al-associated isolates cultured in the outpatient setting
(13,14,16).
Another study limitation is the inability to fully assess
the effect of potential changes in clinical practice during
the 3-year study period. If physicians increased or
decreased the tendency to obtain cultures, these changes
might affect the number or proportion of MRSA isolates
identified each year. However, retrospective examination
of the total number of cultures requested by physicians
each year from 6 acute care hospitals demonstrated that
102,537, 99,772, and 99,461 total cultures were ordered at
these facilities in 2000, 2001, and 2002, respectively.
These data do not suggest any major shift in practice pat-
terns during the relatively short duration of this study.
Therefore, the observed temporal trends cannot likely be
attributed to changing physician practices.
A third possible limitation is that we were unable to
include susceptibility testing data from 4 of Hawaii’s 24
acute care medical centers and their associated outpatient
locations. However, a separate review of antibiogram data
available from all laboratory facilities in the state in 2001
found that in aggregate, the 4 excluded hospital laborato-
ries accounted for only 1,632 (11%) of the 14,539 total S.
aureus isolates identified that year. Therefore, the SHARP
data in this study captured ≈90% of all S. aureus suscepti-
bility testing data in Hawaii from 2000 to 2002. 
To our knowledge, this is the first study of MRSAusing
susceptibility testing data from inpatient and outpatient
settings representative of an entire state population. Our
major finding, substantive and increasing rates of MRSA
in the outpatient setting, is particularly important as reports
of MRSA acquired in the community increase across the
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Figure 2. Proportion of methicillin-resistant Staphylococcus aureus
(MRSA) by 10-year age group and clinical setting, Hawaii
2000–2002.country, and optimal strategies for the management of
MRSA infections in the outpatient setting have yet to be
established (14,16,25,27–30). More studies are needed to
improve the understanding of MRSA epidemiology in the
community and to identify appropriate strategies to pre-
vent S. aureus infections, including MRSA. 
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